OncoTRACE is a new genomic study that deeply analyzes the tumor of the patient and allows to monitor and quantify the mutations of the tumor present in blood (circulating tumor DNA) to quantify the residual disease after the treatment, to detect new mutations and relapses of the tumor before the image techniques and also to monitor the response to the treatment and possible resistences.

First, a tumor block (FFPE) of the patient is analyzed by OncoDEEP to provide the oncologist of treatment options based in the most complete tumor characterization. If in this process we some alterations are identified, these can be follow through the OncoTRACE test in blood.

This test offers important individual information related to the development and progression of the tumor and a more consistent prediction of the response through blood analysis spaced in time approximately 2-3 months ( depending on the routine visits and other specific conditions of patient’s cancer type that the oncologist considers)



Thanks to OncoTRACE the oncologist will have valuable information of the efficacy of the selected patient’s treatment, before the clasique image techniques (García Murillas et al, 2015).

The genomic test OncoTRACE in liquid biopsy (blood) uses the new technology that is able to isolate the circulating tumor DNA (ctDNA) in blood in order to identify genomic alterations (mutations and CNV) through an ultrasequencing panel that includes the analysis of more than 200 hotspot associated to sensitivity or resistance to targeted therapies in 27 genes besides th specific variants detected in the solid biopsy (monitoring)

This test has been developed by OncoDNA.